文献速递胸部肿瘤

卡铂对比两种剂量顺铂联合吉西他滨治疗晚期非小细胞肺癌:英国胸部肿瘤组随机III期试验结果

Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
PubMed 文献 · Eur J Cancer · 2017-08-04

该三臂随机III期试验纳入1363例初治IIIB/IV期非小细胞肺癌患者,比较吉西他滨联合顺铂80 mg/m2、顺铂50 mg/m2或卡铂AUC6的疗效。结果显示三组生存时间有显著差异(p=0.046),GC50组最差(中位8.2个月),GC80组9.5个月,GCb6组10.0个月;卡铂AUC6非劣效于顺铂80 mg/m2(HR=0.93,单侧95%CI上限1.04),但不良事件更多;顺铂50 mg/m2生存更差且未被生活质量改善所补偿。

要点

  • 卡铂AUC6联合吉西他滨在生存上非劣效于顺铂80 mg/m2(HR=0.93,单侧95%CI上限1.04)。
  • 顺铂50 mg/m2组中位生存8.2个月,劣于顺铂80 mg/m2的9.5个月和卡铂AUC6的10.0个月(p=0.046)。
  • 卡铂AUC6组≥3-4级不良事件发生率60%,高于顺铂80 mg/m2组的43%和顺铂50 mg/m2组的30%。

核心结论

  • 与吉西他滨联合时,卡铂AUC6在生存方面非劣效于顺铂80 mg/m2。
  • 卡铂与更多不良事件相关,且未带来更好的生活质量。
  • 顺铂较低剂量50 mg/m2生存更差,且未被更好的生活质量所补偿。

研究设计与样本

  • 三臂随机III期试验,纳入初治IIIB/IV期非小细胞肺癌患者1363例,按1:1:1随机分配。
  • 患者接受吉西他滨1250 mg/m2(第1、8天,3周周期)联合顺铂80 mg/m2(GC80)、顺铂50 mg/m2(GC50)或卡铂AUC6(GCb6),最多4周期。
  • 主要终点为生存时间,旨在检验治疗组间差异并评估非劣效性,预设非劣效界值为风险比(HR)1.2。
  • 次要终点包括缓解率、不良事件和生活质量(QoL)。

主要发现

  • 三组生存时间有显著差异(p=0.046),GC50组最差,中位生存8.2个月,GC80组9.5个月,GCb6组10.0个月。
  • GC50对比GC80的校正HR为1.13(95%CI 0.99-1.29),GC50对比GCb6的校正HR为1.23(95%CI 1.08-1.41)。
  • GCb6非劣效于GC80(HR=0.93,单侧95%CI上限1.04)。
  • 校正生活质量后结果不变。
  • 最佳客观缓解率:GC80组29%,GC50组20%,GCb6组27%(p<0.007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS: The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m2 on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m2 (GC80) or cisplatin 50 mg/m2 (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time, aiming to test for a difference between treatment arms and also assess non-inferiority with pre-defined margin selected as hazard ratio (HR) of 1.2. Secondary outcome measures included response rate, adverse events and quality of life (QoL). FINDINGS: The trial recruited 1363 patients. Survival time differed significantly across the three treatment arms (p = 0.046) with GC50 worst with median 8.2 months compared to 9.5 for GC80 and 10.0 for GCb6. HRs (adjusted) for GC50 compared to GC80 was 1.13 (95% confidence interval [CI] 0.99-1.29) and for GC50 compared to GCb6 was 1.23 (95% CI: 1.08-1.41). GCb6 was significantly non-inferior to GC80 (HR = 0.93, upper limit of one-sided 95% CI 1.04). Adjusting for QoL did not change the findings. Best objective response rates were 29% (GC80), 20% (GC50) and 27% (GCb6), p < 0.007. There were more dose reductions and treatment delays in the GCb6 arm and more adverse events (60% with at least one grade 3-4 compared to 43% GC80 and 30% GC50). INTERPRETATION: In combination with gemcitabine, carboplatin at AUC6 is not inferior to cisplatin at 80 mg/m2 in terms of survival. Carboplatin was associated with more adverse events and not with better quality of life. Cisplatin at the lower dose of 50 mg/m2 has worse survival which is not compensated by better quality of life. CLINICALTRIALS. GOV IDENTIFIER: NCT00112710. EUDRACT NUMBER: 2004-003868-30. CANCER RESEARCH UK TRIAL IDENTIFIER: CRUK/04/009.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ferry D, Billingham L, Jarrett H, et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017. PMID: 28780466. doi:10.1016/j.ejca.2017.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。